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Abstract Addition of gastrin or cholecystokinin octapeptide
(CCK-8) to cultures of Rat-1 cells stably transfected with the
CCK2 (CCKB/gastrin) receptor induced protein kinase D (PKD)
activation that was detectable within 1 min and reached a
maximum (V10-fold) after 2.5 min of hormonal stimulation.
Half-maximal PKD activation for both CCK-8 and gastrin was
achieved at 10 nM. Treatment with various concentrations of the
selective PKC inhibitors Ro 31-8220 or GF-I potently blocked
PKD activation induced by subsequent addition of CCK-8 in a
concentration-dependent fashion. Our results indicate that PKC-
dependent PKD activation is a novel early event in the action of
gastrin and CCK-8 via CCK2 receptors. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Gastrin, produced by G cells in the gastric antrum, has
been identi¢ed as the circulating hormone responsible for
stimulation of acid secretion from the parietal cell [1]. Gastrin
also acts as a potent cellular growth factor that has been
implicated in a variety of normal and abnormal biological
processes including maintenance of the gastric mucosa, pro-
liferation of enterochroma⁄n-like (ECL) cells and neoplastic
transformation [2]. Gastrin, cholecystokinin (CCK) and CCK-
related peptides exert their characteristic e¡ects on cellular
processes by binding to speci¢c guanine nucleotide-binding
regulatory protein (G protein)-coupled receptor (GPCR) sub-
types. The CCK2 (CCKB/gastrin) receptor binds gastrin and
CCK with similar a⁄nity whereas the CCK1 (CCKA) recep-
tor exhibits a 500-fold higher a⁄nity for CCK than for gastrin
(see [3] for review). One of the earliest signal transduction
events induced by activation of CCK2 receptors is the GKq-
mediated stimulation of L isoforms of phospholipase C (PLC)
leading to Ins(1,4,5)P3-mediated Ca2 mobilization from in-
ternal stores and diacylglycerol (DAG) stimulation of classic
and novel isoforms of the protein kinase C (PKC) family.
Accordingly, gastrin stimulates rapid mobilization of Ca2
from intracellular stores in a variety of cell types including
¢broblasts stably transfected with the CCK2 receptor e.g.
Rat-1 [4], NIH 3T3 [5] and CHO [6] and other cell types
that express endogenous CCK2 receptors, including ECL [1]
and small cell lung carcinomas [7,8]. In contrast, direct acti-
vation of PKC isoforms in response to gastrin has been less
frequently measured and the molecular events occurring
downstream of speci¢c isoforms of PKC remain elusive.
Protein kinase D (PKD)/PKCW is a serine/threonine protein
kinase [9,10] with structural, enzymological and regulatory
properties distinct from other members of the PKC family
[11]. For example, the catalytic domain of PKD is distantly
related to Ca2-regulated kinases and the regulatory region of
this kinase contains a putative transmembrane domain, a
pleckstrin homology (PH) domain that regulates enzyme ac-
tivity [12,13], and lacks a sequence with homology to a typical
PKC autoinhibitory pseudosubstrate motif [9,10]. In particu-
lar, PKD is rapidly activated in intact cells through a mech-
anism that involves phosphorylation [11]. Exposure of intact
cells to phorbol esters, bryostatin or mitogenic agonists in-
cluding bombesin and platelet-derived growth factor induces
rapid PKD phosphorylation and activation, which is main-
tained during cell lysis and immunoprecipitation [12,14^17].
Several lines of evidence generated by using PKC-speci¢c in-
hibitors and co-transfection of PKD with constitutively active
PKC mutants, suggest that PKD is activated through a novel
PKC-dependent signal transduction pathway in vivo [13^17].
The heterotrimeric G proteins Gq and Gi have been impli-
cated in mediating PKC-dependent PKD activation in re-
sponse to heptahelical receptor activation [17,18].
Here, we examined whether PKD activation is also an early
event in the action of the hormonal peptides gastrin and sul-
fated CCK octapeptide (CCK-8) using Rat-1 cells expressing
the human CCK2 receptor. These cells have provided a useful
model system to elucidate signal transduction pathways acti-
vated through CCK2 [4], bombesin [19,20] and neuromedin B
[21] receptors. Our results demonstrate that treatment of qui-
escent cultures of these cells with either gastrin or CCK-8
induces a rapid and striking dose-dependent increase in
PKD activity through a PKC-dependent pathway.
2. Materials and methods
2.1. Cell culture
The generation and properties of Rat-1 cells stably transfected with
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human CCK2 receptor (Rat-1CCK2R) have been previously de-
scribed [4]. The cells were maintained at 37‡C in Dulbecco’s modi¢ed
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum
(FBS) and 0.5 mg/ml of geneticin (G418) in a humidi¢ed atmosphere.
For experimental purposes, cells were plated in 100 mm dishes at
3U105 cells/dish and grown in DMEM containing 10% FBS and
were allowed to grow to con£uency (5^7 days) and then changed to
serum-free DMEM for 18^24 h prior to the experiment.
2.2. Immunoprecipitation
Cultures of Rat-1CCK2R cells, treated as described in the individ-
ual experiments, were washed and lysed in 50 mM Tris^HCl pH 7.6,
2 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 1 mM 4-(2-aminoethyl)-benzenesulfonyl £uoride
hydrochloride (AEBSF) and 1% Triton X-100 (lysis bu¡er A). Cell
lysates were clari¢ed by centrifugation at 15 000Ug for 10 min at 4‡C.
PKD was immunoprecipitated at 4‡C for 2^4 h with the PA-1 anti-
serum (1:100), as previously described [14]. The immune complexes
were recovered using protein A coupled to agarose.
2.3. Kinase assay of PKD
PKD autophosphorylation was determined in an in vitro kinase
assay by mixing 20 Wl of PKD immunocomplexes with 10 Wl of a
phosphorylation mixture containing (¢nal concentration) 100 WM
[Q-32P]ATP (speci¢c activity 400^600 cpm/pmol), 30 mM Tris^HCl
pH 7.4, 10 mM MgCl2 and 1 mM DTT. After 10 min of incubation
at 30‡C, the reaction was stopped by washing with 200 Wl of kinase
bu¡er and then adding an equal volume of 2USDS^polyacrylamide
gel electrophoresis (PAGE) sample bu¡er (200 mM Tris^HCl pH 6.8,
2 mM EDTA, 0.1 M Na3VO4, 6% SDS, 10% glycerol and 4% 2-mer-
captoethanol), followed by SDS^PAGE analysis [14,22]. The gels were
dried and the 110 kDa radioactive band corresponding to autophos-
phorylated PKD was visualized by autoradiography. Autoradio-
graphs were scanned in a GS-710 calibrated imaging densitometer
(Bio-Rad), and the labeled band was quanti¢ed using the Quantity
One1 software program.
Exogenous substrate phosphorylation by immunoprecipitated PKD
was carried out by mixing 20 Wl of the washed immunocomplexes with
20 Wl of a phosphorylation mixture containing 2.5 mg/ml syntide
2 (PLARTLSVAGLPGKK), a peptide based on phosphorylation
site two of glycogen synthase. After 10 min of incubation at 30‡C,
the reaction was stopped by adding 100 Wl of 75 mM H3PO4 and
spotting 75 Wl of the supernatant on P-81 phosphocellulose paper.
Free [Q-32P]ATP was separated from the labeled substrate by washing
the P-81 paper four times for 5 min, in 75 mM H3PO4. The papers
C
Fig. 1. Gastrin and CCK-8 stimulate PKD activation in a time-de-
pendent manner. A, upper panel: Time course of gastrin-induced
PKD activation. Con£uent and quiescent cultures of Rat-1CCK2R
cells were washed twice in DMEM and then incubated with 100 nM
gastrin for various times at 37‡C as indicated. Cells were lysed with
lysis bu¡er A and immunoprecipitated with PA-1 antiserum. PKD
activity was determined by an in vitro kinase assay as described in
Section 2 followed by SDS^PAGE and autoradiography. The auto-
radiogram shown is representative of three independent experiments.
Lower panel: Scanning densitometry of gastrin time course. The re-
sults shown are the values (means þ S.E.M., n = 3) of the level of
PKD activation by IVK obtained from scanning densitometry ex-
pressed as a percentage of the maximum increase in phosphoryla-
tion obtained with 100 nM gastrin. Insert: Con£uent and quiescent
cultures of Rat-1CCK2R cells in serum-free DMEM were treated
with 100 nM gastrin for various times at 37‡C. PKD activity in the
immunocomplexes was then measured by syntide 2 phosphorylation,
as described in Section 2. B, upper panel: Time course of CCK-8-
induced PKD activation. Con£uent and quiescent cultures of Rat-
1CCK2R cells were washed twice in DMEM and then incubated
with 100 nM CCK-8 for various times at 37‡C as indicated. Cells
were lysed with lysis bu¡er A and immunoprecipitated with PA-1
antiserum. PKD activity was determined by an in vitro kinase assay
as described in Section 2 followed by SDS^PAGE and autoradiog-
raphy. The autoradiogram shown is representative of three inde-
pendent experiments. Lower panel: Scanning densitometry of CCK-
8 time course. The results shown are the values (means þ S.E.M.,
n = 3) of the level of PKD activation by IVK obtained from scan-
ning densitometry expressed as a percentage of the maximum in-
crease in phosphorylation obtained with 100 nM CCK-8. Insert:
Con£uent and quiescent cultures of Rat-1CCK2R cells in serum-
free DMEM were treated with 100 nM CCK-8 for various times at
37‡C. PKD activity in the immunocomplexes was then measured by
syntide 2 phosphorylation, as described in Section 2. C: Detection
of PKD activation by Western blot analysis using a phospho-specif-
ic antibody directed against the phosphorylated state of the C-termi-
nal serine 916 (pS916). Con£uent and quiescent cultures of Rat-
1CCK2R cells in serum-free DMEM were treated with 100 nM
CCK-8 for 10 min at 37‡C. Western blot analysis using pS916 anti-
serum was performed following lysis of the cells with 2Usample
bu¡er as described in Section 2. The Western blot shown is repre-
sentative of three independent experiments.
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were dried, and the radioactivity incorporated into syntide 2 was
determined by Cerenkov counting.
2.4. Western blot analysis
Quiescent cultures of Rat-1CCK2R cells grown on 100 mm dishes
were washed twice with DMEM and then treated as described. The
cells were lysed in 2USDS^PAGE sample bu¡er. Following SDS^
PAGE on 8% gels, proteins were transferred to Immobilon-P mem-
branes (Millipore) and blocked by 3^6 h incubation with 5% non-fat
milk in phosphate-bu¡ered saline (PBS), pH 7.2. Membranes were
then incubated overnight with an antiserum that speci¢cally recog-
nizes the phosphorylated state of serine 916 of PKD at a dilution
of 1:500 in PBS containing 5% non-fat dried milk. Horseradish per-
oxidase-conjugated anti-rabbit IgG antibody (1:5000, Amersham) was
then applied for 1 h at room temperature after washing three times
with PBS containing 0.05% Tween. Immunoreactive bands were de-
tected by enhanced chemiluminescence Western blotting ECL1 re-
agents (Amersham).
2.5. Materials
[Q-32P]ATP (370 MBq/ml) was from Amersham Pharmacia Biotech
(Piscataway, NJ, USA). GF-I (also known as bisindolylmaleimide I or
GF 109203X) and Ro 31-8220 were purchased from Calbiochem (San
Diego, CA, USA). Sulfated gastrin II, CCK-8, wortmannin, rapamy-
cin, PD 098059, genistein, and DMEM were purchased from Sigma.
Protein A-agarose was from Boehringer Mannheim (Indianapolis, IN,
USA). Geneticin G418 was purchased from Gibco BRL. PA-1 anti-
serum was raised against the synthetic peptide EEREMKALSERV-
SIL that corresponds to the C-terminal region of the predicted amino
acid sequence of PKD, as previously described [14,22]. An antiserum
that speci¢cally recognizes the phosphorylated state of serine 916 of
PKD (pS916) was generously provided by Dr. Doreen Cantrell, Im-
perial Cancer Research Institute, London, UK. Other items were from
standard suppliers or as indicated in the text.
3. Results and discussion
3.1. CCK2 receptor mediates PKD activation
To determine whether gastrin can induce PKD activation in
Rat-1CCK2R cells, quiescent cultures of these cells were
treated with this hormone for increasing times, lysed and
PKD was immunoprecipitated with PA-1 antiserum. The re-
sulting immunocomplexes were incubated with [Q-32P]ATP
and the incorporation of 32P into PKD was analyzed by
SDS^PAGE and autoradiography. As shown in Fig. 1A,
PKD isolated from unstimulated Rat-1CCK2R cells had
low catalytic activity. Treatment of Rat-1CCK2R cells with
gastrin induced a rapid and striking increase in PKD kinase
activity which was maintained during cell lysis and immuno-
precipitation. PKD activation was detectable within 1 min
and reached a maximum (V10-fold) after 2.5 min of gastrin
stimulation.
As an independent measure of PKD activation induced by
gastrin in Rat-1CCK2R cells, we also examined phosphoryla-
tion of an exogenous substrate using syntide 2 [23,24], a pep-
tide identi¢ed as an excellent model substrate for PKD
[9,13,22,25]Consistent with the results of autophosphorylation
assays, syntide 2 phosphorylation assays also showed that
Rat-1CCK2R cells stimulated with gastrin had dramatically
increased PKD activity (Fig. 1A, inset).
The CCK2 receptor binds gastrin and CCK-8 with similar
high a⁄nity [3]. Accordingly, addition of CCK-8 instead of
gastrin to cultures of Rat-1CCK2R cells also induced a rapid
increase in PKD activity, as judged by autophosphorylation
assays (Fig. 1B) and by syntide 2 phosphorylation assays (Fig.
1B, inset). These results demonstrate that PKD activation is
one of the early events induced by gastrin or CCK-8 in this
model system.
Fig. 2. Gastrin and CCK-8 induce PKD activation in a dose-depen-
dent manner. A, upper panel: Dose response of gastrin-induced
PKD activation. Con£uent and quiescent cultures of Rat-1CCK2R
cells were treated with various concentrations of gastrin for 10 min
at 37‡C, as indicated. The cultures were lysed in lysis bu¡er A and
immunoprecipitated with PA-1 antiserum, and PKD activity deter-
mined by an in vitro kinase assay as described in Section 2. The
autoradiogram shown is representative of three independent experi-
ments. Lower panel: Scanning densitometry of gastrin dose re-
sponse. The results shown are the values (means þ S.E.M., n = 3) of
the level of PKD activation from IVK obtained from scanning den-
sitometry expressed as a percentage of the maximum increase in
phosphorylation obtained with 100 nM gastrin. B, upper panel:
Dose response of CCK-8-induced PKD activation. Con£uent and
quiescent cultures of Rat-1CCK2R cells were treated with various
concentrations of CCK-8 for 10 min at 37‡C, as indicated. The cul-
tures were lysed in lysis bu¡er A and immunoprecipitated with PA-
1 antiserum, and PKD activity determined by an in vitro kinase as-
say as described in Section 2. The autoradiogram shown is represen-
tative of three independent experiments. Lower panel: Scanning
densitometry of CCK-8 dose response. The results shown are the
values (means þ S.E.M., n = 3) of the level of PKD activation from
IVK obtained from scanning densitometry expressed as a percentage
of the maximum increase in phosphorylation obtained with 100 nM
CCK-8.
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Recently, an antiserum speci¢cally recognizing the phos-
phorylated form of a PKD C-terminal residue, serine 916,
was developed and used to detect in vivo autophosphorylation
at this site by active PKD [26]. Thus, the pS916 antiserum
provides a novel approach for detecting conversion of PKD to
an active form within cells. Here, lysate from Rat-1CCK2R
cells stimulated with 100 nM CCK-8 for 10 min was analyzed
by SDS^PAGE followed by Western blot analysis using the
pS916 antiserum. CCK-8 stimulation induced a dramatic in-
crease in the immunoreactivity of the PKD band indicative of
phosphorylation at Ser 916 (Fig. 1C).
Stimulation of Rat-1CCK2R cells with increasing concen-
trations of either gastrin or CCK-8 for 10 min induced a
striking dose-dependent increase in PKD activation, as judged
by assays of in vitro PKD kinase activity after immunopreci-
pitation (Fig. 2B). Half-maximal and maximal PKD activa-
tion for both CCK-8 and gastrin was achieved at 10 and 100
nM, respectively (Fig. 2B). In contrast, addition of CCK-8 or
gastrin to cultures of Rat-1 cells untransfected or transfected
with vector did not induce any signi¢cant PKD activation.
Taken together, the results presented in Figs. 1 and 2 pro-
vide multiple lines of evidence indicating that stimulation of
Rat-1CCK2R cells with gastrin or CCK-8 induces rapid and
striking PKD activation.
3.2. CCK-8/gastrin-induced PKD activation is PKC-dependent
In order to elucidate the role of PKCs in PKD activation
induced by gastrin or CCK-8, cultures of Rat-1CCK2R cells
were treated with various concentrations of the selective PKC
inhibitors Ro 31-8220 [27] or GF-I [28] prior to gastrin/CCK-
8 stimulation. (Fig. 3A, upper panels, left and right) As shown
in Fig. 3A (upper panel), treatment with the PKC inhibitors
potently blocked PKD activation induced by subsequent ad-
dition of CCK-8 in a concentration-dependent fashion. Max-
imal inhibition of PKD activation (V90%) was achieved at
1 WM of each inhibitor. In contrast, Ro 31-8220 or GF-I
added directly to the in vitro kinase assay, even at the con-
centrations (0.25^1 WM) that abrogated CCK-8-induced PKD
activation in intact Rat-1CCK2R cells, did not inhibit PKD
activity (Fig. 3A, lower panel). These results imply that Ro
31-8220 and GF-I do not inhibit PKD activity directly but
interfere with gastrin/CCK-8-mediated PKD activation in in-
tact cells by blocking PKC.
In contrast to the results obtained with GF-I or Ro 81-
3220, treatment of Rat-1CCK2R cells with the broad spec-
trum protein tyrosine kinase inhibitor genistein, the MEK
inhibitor PD098059 [29] which prevents ERK activation, the
phosphoinositide 3-kinase inhibitor wortmannin [30] or rapa-
mycin [31] which interfere with activation of the phosphoino-
sitide 3-kinase downstream target p70 ribosomal S6 kinase
(p70S6K) did not interfere with gastrin-induced PKD activa-
tion. (Fig. 4). These results demonstrate the speci¢city of the
PKC inhibitors and indicate that these kinases are not up-
stream regulators of PKD.
Fig. 3. CCK2R induces PKD activation through a PKC-dependent pathway. A: PKC inhibitors Ro 31-8220 and GF-I inhibit CCK-8-induced
PKD activation. Con£uent Rat-1CCK2R cells were incubated for 1 h with di¡erent concentrations of the PKC inhibitor Ro 31-8220 (A, left
upper panel) or GF-I (A, right upper panel). Control cells (3) received equivalent amount of solvent. The cultures were subsequently stimu-
lated for 10 min with 100 nM CCK-8 at 37‡C. Cells were lysed with lysis bu¡er A and immunoprecipitated with PA-1 antiserum. PKD activity
was then determined by an in vitro kinase assay, as described in Section 2. Parallel cultures were treated for 10 min with 100 nM CCK-8 at
37‡C (A, lower panels). Cells were lysed with lysis bu¡er A and immunoprecipitated with PA-1 antiserum. PKD activity was then determined
by an in vitro kinase assay in absence or presence of the indicated concentrations of Ro 31-8220 or GF-I added to the incubation mixture. B:
Scanning densitometry. The results shown are the values (means þ S.E.M., n = 3) of the level of PKD activation obtained from scanning densi-
tometry expressed as a percentage of the maximum increase in phosphorylation obtained from cells incubated with 100 nM CCK-8 for 10 min
at 37‡C. Values corresponding to PKD activity from cells incubated with Ro 31-8220 or GF-I are represented by circles. Values corresponding
to PKD activity that was determined by an in vitro kinase assay in the presence of the indicated concentrations of GF-I or Ro 31-8220 added
to the incubation mixture are represented by triangles.
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3.3. Conclusions
In addition to its role in gastric acid secretion, gastrin also
acts as a potent cellular growth factor that has been impli-
cated in a variety of normal and abnormal biological process-
es including maintenance of the gastric mucosa, proliferation
of ECL cells and neoplastic transformation. An association
between hypergastrinemia and proliferation of ECL cells,
sometimes leading to formation of gastric carcinoid tumors,
is now well established in rats [32] and in humans [33,34].
Epidemiological evidence also has been obtained that impli-
cates hypergastrinemia as a factor in development of colorec-
tal cancer [35]. Colorectal carcinomas have been found to
produce progastrin-related peptides and CCK2 receptors
[36^38]. Thus, there is considerable interest in the elucidation
of the signal transduction pathways that mediate the biolog-
ical e¡ects of the multifunctional agonists gastrin and CCK.
PKC, a major target for the tumor promoting phorbol es-
ters, has been implicated in the signal transduction pathways
that mediate a wide range of biological responses in response
to growth factors, hormones, neuropeptides and cellular on-
cogenes [39^41]. Although some studies, using pharmacolog-
ical inhibitors, have implicated PKC in CCK2 receptor-medi-
ated signal transduction [42,43], direct activation of PKC
isoforms in response to gastrin has been less frequently mea-
sured. PKD is a novel serine/threonine protein kinase that can
be distinguished from PKC isoforms by a variety of criteria
including catalytic domain structure, substrate speci¢city, the
presence of a PH domain and absence of a pseudosubstrate
autoinhibitory motif which is present in all known PKCs up-
stream of the ¢rst cysteine-rich domain [11]. PKD has been
implicated in the regulation of EGF receptor signaling [44],
Na/H antiport activity [45], Golgi organization and func-
tion [46,47], NFkB-mediated gene expression [48] and cell
migration [49]. The results presented here demonstrate that
stimulation of Rat-1CCK2R cells with gastrin or CCK-8 in-
duces a rapid and striking dose-dependent increase in PKD
activity through a PKC-dependent pathway. Our ¢ndings
identify PKD activation as a novel early event in the action
of gastrin and CCK-8 via the CCK2 receptor.
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100 nM gastrin. Cell lysates were immunoprecipitated with PA-1
antiserum, and PKD activity was determined by an in vitro kinase
assay, followed by SDS^PAGE and autoradiography. The results
shown are the values (means þ S.E.M., n = 3) of the level of PKD
activation from IVK obtained from scanning densitometry expressed
as a percentage of the maximum increase in phosphorylation ob-
tained with 100 nM gastrin.
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